Arete Wealth Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.95M | Buy |
31,600
+803
| +3% | +$173K | 0.53% | 50 |
|
|
2026
Q1 | $6.7M | Sell |
30,797
-1,776
| -5% | -$394K | 0.5% | 51 |
|
|
2025
Q4 | $7.44M | Buy |
32,573
+1,884
| +6% | +$429K | 0.52% | 53 |
|
|
2025
Q3 | $7.1M | Buy |
30,689
+133
| +0.4% | +$27.1K | 0.44% | 51 |
|
|
2025
Q2 | $5.67M | Sell |
30,556
-1,261
| -4% | -$234K | 0.4% | 54 |
|
|
2025
Q1 | $6.67M | Buy |
31,817
+586
| +2% | +$114K | 0.51% | 41 |
|
|
2024
Q4 | $5.54M | Buy |
31,231
+6,445
| +26% | +$1.18M | 0.4% | 53 |
|
|
2024
Q3 | $4.89M | Buy |
+24,786
| New | +$4.63M | 0.42% | 54 |
|
|
2024
Q2 | – | Sell |
-385,299
| Closed | -$69.9M | – | 727 |
|
|
2024
Q1 | $69.9M | Buy |
385,299
+6,464
| +2% | +$1.11M | 6.46% | 1 |
|
|
2023
Q4 | $58.6M | Buy |
+378,835
| New | +$55.2M | 4.47% | 1 |
|
|
2023
Q3 | – | Sell |
-374,265
| Closed | -$50.4M | – | 509 |
|
|
2023
Q2 | $50.4M | Buy |
374,265
+7,223
| +2% | +$1.06M | 4.45% | 1 |
|
|
2023
Q1 | $58.5M | Buy |
367,042
+14,326
| +4% | +$2.19M | 4.76% | 2 |
|
|
2022
Q4 | $57B | Buy |
352,716
+13,907
| +4% | +$2.13M | 4.99% | 2 |
|
|
2022
Q3 | $45.5M | Buy |
338,809
+314,279
| +1,281% | +$45.1M | 4.45% | 2 |
|
|
2022
Q2 | $3.76M | Sell |
24,530
-272,179
| -92% | -$41.6M | 0.38% | 57 |
|
|
2022
Q1 | $48.1M | Buy |
296,709
+2,668
| +0.9% | +$388K | 4.03% | 2 |
|
|
2021
Q4 | $39.8M | Buy |
294,041
+279,589
| +1,935% | +$33M | 3.39% | 3 |
|
|
2021
Q3 | $1.57M | Buy |
14,452
+808
| +6% | +$92.3K | 0.17% | 115 |
|
|
2021
Q2 | $1.31M | Buy |
13,644
+229
| +2% | +$25.8K | 0.18% | 107 |
|
|
2021
Q1 | $1.45M | Buy |
13,415
+1,908
| +17% | +$204K | 0.19% | 116 |
|
|
2020
Q4 | $1.22M | Sell |
11,507
-4,240
| -27% | -$407K | 0.17% | 121 |
|
|
2020
Q3 | $1.36M | Sell |
15,747
-144
| -0.9% | -$13.6K | 0.21% | 117 |
|
|
2020
Q2 | $1.56M | Buy |
15,891
+3,026
| +24% | +$266K | 0.27% | 96 |
|
|
2020
Q1 | $961K | Sell |
12,865
-4,354
| -25% | -$371K | 0.19% | 122 |
|
|
2019
Q4 | $1.53M | Buy |
17,219
+8,022
| +87% | +$666K | 0.27% | 92 |
|
|
2019
Q3 | $696K | Buy |
9,197
+1,295
| +16% | +$88.8K | 0.13% | 180 |
|
|
2019
Q2 | $575K | Sell |
7,902
-4,669
| -37% | -$367K | 0.11% | 202 |
|
|
2019
Q1 | $1.01M | Sell |
12,571
-2,466
| -16% | -$202K | 0.21% | 124 |
|
|
2018
Q4 | $1.39M | Buy |
15,037
+1,419
| +10% | +$125K | 0.34% | 71 |
|
|
2018
Q3 | $1.29M | Buy |
13,618
+121
| +0.9% | +$11.5K | 0.29% | 81 |
|
|
2018
Q2 | $1.25M | Buy |
13,497
+2,039
| +18% | +$199K | 0.3% | 81 |
|
|
2018
Q1 | $1.08M | Buy |
11,458
+3,063
| +36% | +$336K | 0.36% | 66 |
|
|
2017
Q4 | $812K | Sell |
8,395
-1,875
| -18% | -$177K | 0.26% | 107 |
|
|
2017
Q3 | $913K | Sell |
10,270
-212
| -2% | -$16.1K | 0.36% | 84 |
|
|
2017
Q2 | $760K | Buy |
10,482
+798
| +8% | +$53.6K | 0.35% | 82 |
|
|
2017
Q1 | $631K | Buy |
9,684
+366
| +4% | +$23K | 0.28% | 80 |
|
|
2016
Q4 | $584K | Buy |
9,318
+4,696
| +102% | +$287K | 0.27% | 85 |
|
|
2016
Q3 | $292K | Buy |
+4,622
| New | +$299K | 0.17% | 109 |
|
|
2016
Q2 | – | Sell |
-8,919
| Closed | -$509K | – | 141 |
|
|
2016
Q1 | $509K | Hold |
8,919
| – | – | 0.3% | 61 |
|
|
2015
Q4 | $528K | Sell |
8,919
-25
| -0.3% | -$1.44K | 0.32% | 56 |
|
|
2015
Q3 | $487K | Sell |
8,944
-816
| -8% | -$53.1K | 0.38% | 58 |
|
|
2015
Q2 | $656K | Sell |
9,760
-7,027
| -42% | -$459K | 0.44% | 53 |
|
|
2015
Q1 | $983K | Buy |
+16,787
| New | +$1.01M | 0.63% | 35 |
|
Other funds holding ABBV
Arete Wealth Advisors's ABBV Position: Q2 2026 in Review
Arete Wealth Advisors increased its AbbVie (ABBV) stake by 2.6% in Q2 2026, buying an estimated $173K and bringing the position to 31,600 shares worth $7.95M. The position accounts for 0.53% of the portfolio, ranked #50.
Arete Wealth Advisors first reported a position in ABBV in Q1 2015 and has held it in 43 quarters since. The position peaked at $57B in Q4 2022. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Arete Wealth Advisors held 31,600 shares of AbbVie worth $7.95M as of Q2 2026.
- Arete Wealth Advisors bought 803 AbbVie shares in Q2 2026, an estimated $173K.
- AbbVie made up 0.53% of Arete Wealth Advisors's portfolio in Q2 2026, its #50 holding.
- Arete Wealth Advisors first reported a position in AbbVie in Q1 2015 and has held it in 43 quarters since.
- Arete Wealth Advisors's AbbVie position peaked at $57B in Q4 2022.
- 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Arete Wealth Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.